Anebulo Pharmaceuticals Announces Voluntary Delisting Plan

Anebulo Pharmaceuticals announced that the company's board of directors has approved the voluntary delisting of the company's common stock from the Nasdaq Capital Market and the subsequent voluntary deregistration of its common stock with the SEC. Simultaneously with this announcement, Anebulo notified Nasdaq today of its intention to voluntarily delist its shares of common stock from Nasdaq. The company is in compliance with applicable Nasdaq listing requirements, but the board believes that the cost of being an SEC reporting company outweighs the benefits. As the company continues with its efforts to maximize value from its lead product candidate, the board has determined that the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages to the company and the holders of its common stock.